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HipHopsame by identifying the selective three dimensional (3D) pharmacophore map for T-type cal-
cium channel blockers (CCBs). Using HipHop module in the CATALYST 4.10 software, both
selective and non-selective HipHop pharmacophore maps for T-type CCBs were developed to
identify its important common pharmacophoric features. HipHop pharmacophore map of
the selective T-type CCBs contained six different chemical features, namely ring aromatic
(R), positive ionizable (P), two hydrophobic aromatic (Y), hydrophobic aliphatic (Z), hydrogen
bond acceptor (H) and hydrogen bond donor (D). However, non-selective T-type CCBs contain
all the above mentioned features except ring aromatic (R). The present ligand-based pharma-
cophore mapping approach could thus be utilized in classifying selective vs. non-selective T-
type CCBs. Further, the model can be used for virtual screening of several small molecule
databases.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The voltage gated calcium (Ca2+) channels (VGCCs), in
response to membrane depolarization, mediate the rapid influx
of extracellular Ca2+ ions into the cytosol of electrically exci-
table cells [1,2]. The increase in the cytosolic Ca2+ level can
cause a cascade of responses in different types of cells. This
includes activation of calcium dependent enzymes, hormones
and neurotransmitter secretion, neurite outgrowth or retrac-
tion, cellular proliferation and differentiation, apoptosis and
gene expression [1–4].
The VGCCs are composed of distinct subunits encoded by
multiple genes and thereby forming a multi-complex structure.
Among these, a1 subunit is the largest with ten multiple forms.
It contributes to the diverse pharmacological and electrophys-
iological properties of VGCCs [3]. Three subfamilies of VGCCs
are identified, which encode Cav1, Cav2, and Cav3 genes,
respectively. The Cav1 subfamily consists of Cav1.1-Cav1.4
channels, which are high-voltage activated (HVA). They medi-
ate L-type Ca2+ current, which requires strong depolarization
for activation. The Cav2 subfamily consists of Cav2.1-Cav2.3,
which includes a1A, a1B, and a1E HVA channels. They mediate
P/Q-type, N-type, and R-type Ca2+ currents, respectively. L-
type Ca2+ currents initiate contraction and secretion in the
muscles and endocrine cells. P/Q-type, N-type, and R-type
Ca2+ currents are primarily expressed in neurons. They are
involved in neurotransmission and mediate calcium transport
into cell bodies and dendrites. The Cav3 subfamily also referred
to as T-type Ca2+ currents consisting of Cav3.1-Cav3.3 includes
a1G, a1H, and a1I channels. These channels generate low-
voltage-activated (LVA) Ca2+ currents [3–5].
T-type Ca2+ channels are expressed in a wide variety of
cells and contribute to neuronal excitability. These channels
also play crucial roles in the control of blood pressure [6].
Under pathological conditions, T-type Ca2+ channels are
known to be implicated in the pathogenesis of epilepsy, neuro-
pathic pain, autism, hypertension, atrial fibrillation, congenital
heart failure, pain, psychoses, and cancer [2,7–9]. Therefore,
these Ca2+ channels are important therapeutic targets for
the treatment of peripheral and central nervous system
(CNS) disorders as well as cardiovascular diseases [10,11].
However, limited progress has been made till date in the quest
to identify both selective and non-toxic T-type CCBs [12,13].
All first generation CCBs such as nifedipine and diltiazem
block L-type Ca2+ channels. They are classified as dihydropy-ridine or non-dihydropyridine agents. The second and third
generation CCBs are either slow release or long acting formu-
lations of the first generation CCBs [14]. The therapeutic use of
most of the CCBs is often limited due to its various side effects,
such as negative inotropism, atrioventricular blockade or neu-
rohormonal activation. Mibefradil drug despite various
adverse effects such as negative inotropism, reflex tachycardia,
negative chronotropic, ankle edema, and constipation was
launched in the market in 1997. However, mibefradil was with-
drawn within a year, due to its potential drug-drug interactions
[15]. Thus, based on this observation there is a need for the
development of new T-type CCBs, having high potency with
fewer side effects.
Computational techniques such as three dimensional (3D)
pharmacophore mapping, quantitative structure-activity rela-
tionship (QSAR) modeling, molecular docking, molecular
dynamics simulation, and virtual screening (VS) have proven
their usefulness in pharmaceutical research for the selection/
identification and/or design/optimization of new chemical enti-
ties [16]. 3D pharmacophore modeling including ligand-based
and structure-based was important areas in Chemoinformat-
ics. Its advances have widened the scope of rational drug
design and the search for the mechanism of drug action. Fur-
ther, it was well-established that the chemical and pharmaco-
logical effects of a compound are closely related to its
physicochemical properties, which can be calculated by vari-
ous methods from the molecular structure. These models are
useful because they rationalize a large number of experimental
observations and allow for saving both time and cost in the
drug discovery process. In addition, in silico methods can
expand VS of compounds that do not exist physically in the
chemical collections therefore compensating for some of the
most important limitations of the high-throughput methods
[17]. Review of literature survey showed extensive use of these
methods in different clinical case studies. Sanaz et al. devel-
oped 3D HipHop pharmacophore model containing six chemi-
cal features by taking four clinically relevant Topoisomerase I
inhibitors. Using Hypo1, they VS Drug like Diverse database
to obtain five structures which were found to be a possible
anti-Topoisomerase I hits [18]. Another research group con-
ducted 3D pharmacophore model based inhibitor screening
and molecular interaction studies for identification of potential
drugs on calcium activated potassium channel blockers. They
identified in this study two compounds showing promising
pharmacophoric fit and ADMET profile [19]. Adane et al. per-
Pharmacophore model for T-Type calcium channel blockers 933formed four features based 3D pharmacophore model screen-
ing to identify potential Plasmodium falciparum dihydrofolate
reductase (PfDHFR) inhibitors. This study used HipHop from
Catalyst program, molecular docking, and interaction analysis
of the active site of the PfDHFR enzyme [20]. 3D-
Pharmacophore model for the T-type CCBs based on 3,4-
dihydroquinazoline and piperazinylalkylisoxazole derivatives
was also reported by other research groups [14].
The main objective of the present work was to develop a 3D
HipHop pharmacophore model for selective vs. non-selective
T-type CCBs using common-feature based pharmacophoric
approach implemented in the HipHop module of Catalyst
[21–23].Experimental
Chemical data
A series of 25 T-type CCBs belonging to the category of 3, 4-
dihydroquinazolines derivatives were selected for the present
study [24–26]. The dataset for common feature pharma-
cophore modeling (HipHop) includes a training set of five
compounds consisting of selective (Compounds A, B and C)
and non-selective (Compounds D and E) T-type CCBs. The
3D pharmacophore model was validated using a test set of
20 T-type CCBs. The chemical structures of training set and
test set compounds along with their biological activity and
selectivity data are presented in Fig. 1 and Table 1 respectively.Fig. 1 Training set compounds for pharmacophore model generation
E are non-selective T-type CCBs.The compounds for developing 3D HipHop pharma-
cophore model were constructed using the standard geometric
parameters of the molecular modeling software package,
SYBYL7.1 (Tripos Associates Inc.). Initially, the compound
geometry optimizations and energy minimizations were per-
formed using PM3 method of MOPAC interfaced in
SYBYL7.1 [27].
In HipHop, conformational flexibility of compounds is
addressed by performing conformational analysis prior to
pharmacophoric hypothesis generation and considering in turn
each single conformer of all the compounds. The CATALYST
program incorporates two methods of conformational model
generation, namely Best fit and Fast fit. Both methods use a
CHARMm force field recent version for energy calculations
and a Poling mechanism for forcing the search into unexplored
regions of conformer space [22]. Best method searches the con-
formational space more extensively than Fast method, partic-
ularly ring conformations. This method applies more stringent
minimization procedures [21]. For each of the training set com-
pounds, a conformational database was generated using the
‘best’ option and default catalyst conformation generation
parameters (a maximum of 255 conformers in an energy range
0–20 kcal/mol from the global minimum) were selected. The
HipHop pharmacophore map was based on the alignment of
common features present in highly potent compounds. It
performs an exhaustive search starting with the simplest
pharmacophore configuration, i.e. possible combinations of
two-feature pharmacophores. Once all two-feature configura-
tions are exhausted, it then moves to the three-feature combi-s. Compounds A, B and C are selective T-type CCBs, while D and
Table 1 The chemical structure of different T-type CCBs along with its IC50 and selectivity.
(continued on next page)
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Table 1 (continued)
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Table 2 The 3D pharmacophore strategy used in Case I and Case II.
Compound IC50 (lM) Selectivity (T/N type) Case I Case II
Trial 1 Trial 2 Trial 3 Trial 1
P O P O P O P O
A 0.56 100 2 0 2 0 2 0 2 0
B 0.96 100 2 0 1 1 1 0
C 4.10 100 2 0 1 1 1 0 2 0
D 1.34 1.4 2 0
E 0.38 32.2 2 0
P: Principle Number, O: Maximum Omitted Feature.
936 T. Gandhi et al.nations. The process continues until HipHop can no longer
generate common pharmacophore combinations. Once all
configurations are generated they are scored. The hypotheses
are ranked on the basis of the number of members fitting the
pharmacophore and the frequency of its occurrence. The qual-
ity of the mapping between a compound and a hypothesis is
indicated by the pharmacophoric fit value.
Present methodology of 3D HipHop pharmacophore model
development was sufficient. Since, in the ligand-based 3D phar-
macophoremodel we could not achieve the bioactive conforma-
tion of the studied compounds in the absence of the
experimental 3D structure of T-type calcium channel receptor.
So the conformation generation protocol adopted by us in the
present ligand-based technique as explained above was justified.Table 3 Statistical summary of ten hypotheses in Case I, Trial
2.
Hypothesis Feature Rank Direct hit Partial hit
1 RPYYZDH 62.00 111 000
2 PYYYZZD 61.84 111 000
3 RPYYZDH 57.77 110 001
4 PYYYZZD 55.90 011 100
5 PYYYZDH 55.87 011 100
6 RPYYZH 55.84 111 000
7 RPYYZDH 55.76 011 100
8 PYYYZZH 55.75 011 100
9 RPYYZDH 55.74 011 100
10 PYYYZDH 55.56 011 100
P: Positive ionizable, H: Hydrogen bond acceptor, Y: Hydrophobic
aromatic, Z: Hydrophobic aliphatic, R: Ring aromatic, HD:
Hydrogen bond donor.
Table 4 Case I and Case II best fit and fast fit values of the trainin
Comp. No. IC50 (lM) Selectivity (T/N type)
Trial 1
B F
A 0.56 100 2.99 3.00
B 0.96 100 1.92 1.76
C 4.10 100 2.21 1.79
D 1.34 1.4
E 0.38 32.2
H2 and H6: Hypotheses 2 and 6, B: Best fit, F: Fast fit.Generation of 3D HipHop pharmacophore model
3D HipHop pharmacophoric features in the present study of
selective and non-selective T-type CCBs were generated using
CATALYST version 4.10 program [21]. The correct represen-
tation of the 3D-chemical features and the appropriate sam-
pling of the conformational space for the 3D pharmacophore
mapping were performed. These include, hydrogen bond
donors/acceptors, hydrophobic, hydrophobic aliphatic/aro-
matic, and charged centers, with the default definitions of
the chemical features being customizable. A maximum of five
types of chemical features can be specified for 3D HipHop
pharmacophore map generation. The number of appearances
of a particular chemical feature was customizable for a mini-
mum of zero and maximum of five respectively. In the HipHop
pharmacophore map, the chemical features that have direc-
tionality (hydrogen bond donor and hydrogen bond acceptor)
are described using two points. On the other hand, non-
directional features such as charged centers, ring aromatic fea-Table 5 Statistical summary of ten hypotheses in Case II.
Hypothesis Feature Rank Direct hit Partial hit
1 PYYDH 53.09 1111 0000
2 PYYZH 52.81 1111 0000
3 PYYDH 52.76 1111 0000
4 PYYZH 52.51 1111 0000
5 PYYZD 52.50 1111 0000
6 PYYZH 52.44 1111 0000
7 PYZDH 52.25 1111 0000
8 PYYZH 52.20 1111 0000
9 RPYDH 52.16 1111 0000
10 PYYDH 52.13 1111 0000
g set compounds for statistically best hypothesis.
Case I Case II
Trial 2 (H2) Trial 2 (H6) Trial 3 Trial 1
B F B F B F B F
6.97 7.00 5.99 6.00 1.96 1.10 5.00 5.00
4.59 3.46 3.50 2.13 5.98 5.96
3.76 1.60 3.06 1.32 6.00 6.00 4.19 1.63
1.39 3.75
3.63 2.68
Fig. 2 The best selective pharmacophore map (a) Case I, Trial 2, Hypothesis 2, and (b): Case I, Trial 2, Hypothesis 6.
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gle points respectively.
3D HipHop pharmacophore model was generated using
two different approaches: (i) Pharmacophore map developed
using three compounds (A, B and C) belonging to 3,4-
dihydroquinazoline class and reported to be highly selective
toward T-type Ca2+ channel, and (ii) Non-selective pharma-
cophore map developed by leveraging four compounds (which
includes both selective and non-selective T-type CCBs (D and
E), with selectivity ranging between 100% and 1.4%). These
two 3D pharmacophore maps generated are then compared
to reveal pharmacophoric features responsible for selective
and non-selective T-type Ca2+ channel inhibition.
Case I: T-type selective 3D HipHop pharmacophore map
Molecular structure of three compounds (A, B and C) belong-
ing to the category of 3,4-dihydroquinazoline derivatives andhighly selective toward T-type Ca2+ channel is shown in
Fig. 1. These molecules are used for developing T-Type chan-
nel selective 3D pharmacophore map. Compounds B and C
differed only in the substituent’s i.e. methyl in compound B
and fluorine in compound C. A methyl group in compound
B can act as hydrogen bond donors and fluorine in compound
C as hydrogen bond acceptor feature respectively.
The feature dictionary for 3D HipHop pharmacophore
map generation was decided based on the functional mapping
of chemical features using three training set compounds (A, B
and C). The chemical feature dictionary, thereby included six
different features, hydrogen bond acceptor/donor (H/D),
hydrophobic aromatic (Y) and aliphatic (Z), ring aromatic
(R) and positive ionizable (P) features respectively. Also, the
hydrogen bond acceptor feature was modified to include fluo-
rine in the feature dictionary, since Compound C belonging to
training set had fluorine atom substitution as the hydrogen
bond acceptor. For the development of selective 3D HipHop
Table 6 Best fit and Fast fit values of test set compounds for statistically best selective and non-selective hypothesis.
Compound Selective hypothesis Non-selective hypothesis
Hypothesis 2 Hypothesis 6
Best fit Fast fit Best fit Fast fit Best fit Fast fit
1 NM NM NM NM 1.99 1.82
2 NM NM NM NM 2.36 2.08
3 NM NM NM NM 4.63 3.59
4 3.02 1.20 3.86 2.72 4.09 2.41
5 NM NM NM NM 4.66 4.09
6 NM NM NM NM 4.25 3.44
7 NM NM NM NM NM NM
8 NM NM NM NM NM NM
9 NM NM NM NM 2.61 1.71
10 NM NM NM NM 4.60 3.84
11 NM NM NM NM 4.53 4.06
12 NM NM NM NM 1.70 1.60
13 NM NM NM NM 2.39 2.29
14 0.25 0.16 NM NM 0.35 0.40
15 NM NM NM NM 4.05 3.64
16 6.36 4.84 NM NM 4.23 3.84
17 NM NM NM NM 1.26 0.39
18 NM NM 5.87 3.35 4.45 3.94
19 NM NM NM NM 4.23 4.11
20 NM NM 5.64 4.65 3.82 3.72
Compound A – – – – – –
Compound B – – – – 4.75 3.67
Compound C – – – –
Mibefradil D NM NM NM NM – –
Compound E NM NM NM NM – –
NM: Not Mapping, Compounds A, B and C are training set for Case I while Compounds A, C, D and E are training set for Case II.
Fig. 3 Pharmacophore mapping of most selective (potent) compound A to selective hypothesis 2.
938 T. Gandhi et al.pharmacophore model the following three trials (Trial 1, Trial
2 and Trial 3 presented in Table 2) described below were con-
sidered in the present study.
Trial 1: All three training set compounds (A, B and C) were
taken as the reference compound by allotting each of them
‘‘Principal” value of 2 and ‘‘MaxOmitFeat” value of 0. This
was to ensure that all chemical features present in them will
be captured while generating 3D pharmacophoric hypotheses,
and is presented in Table 2.Trial 2: In Trial 2, only the highly potent compound, com-
pound A, among three (A, B and C) compounds was taken as
the reference compound. Compound A was given ‘‘Principal”
value of 2 and ‘‘MaxOmitFeat” value of 0. The rest of the
two compounds (B and C) were given the value of 1 for both
‘‘Principal” value and ‘‘MaxOmitFeat” value. This was to
ensure further that their chemical features will be considered
at least once when generating pharmacophoric hypotheses
shown in Table 2.
Fig. 4 Pharmacophore mapping of compounds B and C to selective hypothesis 6.
Fig. 5 Pharmacophore mapping of the most selective (potent) compound A to selective hypothesis 6.
Pharmacophore model for T-Type calcium channel blockers 939Trial 3: In Trial 3, only the highly potent compound, com-
pound A, among three (A, B and C) compounds was taken as
the reference compound. Compound A was given ‘‘Principal”
value of 2 and ‘‘MaxOmitFeat” value of 0. The rest of the
two compounds (B and C) were given the value of 1 for ‘‘Prin-
cipal” value and ‘‘MaxOmitFeat” to be 0, and are presented in
Table 2.
All other parameters were kept at default in these three trial
cases, Trial 1, Trial 2 and Trial 3 for generating pharma-
cophoric hypothesis. Two different methods ‘fast fit’ and ‘best
fit’ were used to generate and compare the 3D pharmacophore
features for selective and non-selective T-type CCBs, as
explained earlier.Case II: Non-selective 3D HipHop pharmacophore map
A non-selective 3D chemical feature hypothesis for the T-type
CCBs was developed in this study. The training sets used in
Case I (Compounds A, B and C) were modified by including
Mibefradil (Compound D) and replacing compound B with
compound E, which was less selective to T-Type channel. Sim-
ilar to Case I, three trials were performed in Case II using the
same chemical Feature dictionary as in Case I. Data related to
Trials 2 and 3 were not shown, and were insignificant as com-
pared to Trial 1. Trial 1 was developed by using ‘‘Principal”
value of 2 and ‘‘MaxOmitFeat” value of 0 for all the four com-
pounds (A, C, D and E) employed in HipHop pharmacophore
map development, as shown in Table 2.
Fig. 6 The best non-selective pharmacophore map (Case II, hypothesis 4).
Fig. 7 Pharmacophore mapping of selective (potent) compound A to non-selective hypothesis 4.
940 T. Gandhi et al.3D HipHop pharmacophore map validations
The 3D pharmacophore hypotheses so engendered in Case I
and Case II were validated by rigorously checking them
against a test set of 20 compounds (inclusive of Mibefradil
for Case I) and 21 compounds (exclusive of Mibefradil to CaseII) respectively. The power to distinguish selective T-type
CCBs vs non-selective T-type CCBs was kept as a criterion
to qualify for valid 3D pharmacophore hypothesis for Case
I, while in Case II study, all compounds should map since it
is not restrictive. Both best fit and fast fit methods were
employed in these two case studies.
Pharmacophore model for T-Type calcium channel blockers 941Results and discussion
3D Pharmacophore model development of selective and non-
selective T-type CCBs was developed using a HipHop module
in Catalyst software [21]. In silico techniques offer attractive
advantages over experimental methods, especially for
membrane/channel receptors. These are difficult to purify/
crystallize for solving the 3D structure of T-type channel
receptor using either X-ray or NMR techniques. So, instead
of structure-based modeling study, ligand-based pharma-
cophore modeling approach was adopted in the present study.
3D model should be robust and significant enough to distin-
guish between selective and non-selective T-type CCBs.
Schuster, reviewed different ligand based and structure
based pharmacophore models followed by Chemoinformatics
techniques to identify potent inhibitors by sequential VS in
hydroxysteroid dehydrogenase/reductases [28]. Structure-
based VS techniques were adopted by Leung et al. to identify
natural product-like STAT3 dimerization inhibitor. STAT3 is
an important druggable target which on dysregulation leads to
a variety of solid and hematological tumors, including leuke-
mia, lymphomas, head and neck cancer [29]. Zhong et al.
developed structure-based VS and optimization of cytisine
derivatives as inhibitors of the menin–MLL interaction. They
identified inhibitors, which exhibited potent anti-proliferative
activity in heptacellular carcinoma cells, possibly through inhi-
bition of Menin–MLL interactions [30]. Pharmacophore map-
ping, molecular docking and QSAR analysis for AChE
inhibitors were performed by Brahmachari et al. to understand
the structural features required for interaction with the AChE
enzyme and its intermolecular interactions with the active site
residues [31].
In the present study, various ligand-based 3D pharma-
cophoric strategies were adopted by us to develop selective
and non-selective HipHop pharmacophore models using dif-
ferent T-Type CCBs.Table 7 Comparative pharmacophore distance map analysis of sele
Features
Selective Hypothesis 2
P-H
P-Y(1) 2.25–4.25
P-Y(2) 4.25–6.25
P-Z(1) 3.27–5.27
P-Z(2) 4.18–6.18
P-R 8.30–10.30
P-HD 6.36–8.73
Z(1)-H
Z(1)-Z(2) 6.03–8.03
Z(1)-Y(1) 4.23–6.23
Z(1)-Y(2) 5.27–7.27
Z(1)-R 8.45–10.45
The distance tolerance range in three hypotheses is measured from posi
features.
P: Positive ionizable, H: Hydrogen bond acceptor, Y (1) and (2): Hydroph
R: Ring aromatic, HD: Hydrogen bond donor.Case I: Selective 3D HipHop pharmacophore features
Trial 1: In Trial 1, using three training set compounds (A, B
and C) as the reference compound by allotting each of them
‘‘Principal” value of 2 and ‘‘MaxOmitFeat” value of 0, the
pharmacophore hypothesis was generated. Three different
chemical features (PYH and PZH) appeared in developing
3D pharmacophore maps. Ten different hypotheses generated
showed only three chemical features with very low scores rang-
ing from 34.4 to 31.8 in this Case I study. The corresponding
best fit and fast fit values are very less and not correlating w.
r.t its T-type channel activity. Thus, the present Case I hypoth-
esis was not very specific due to the presence of less number of
chemical features and is presented in Suppl. Table 1. This in
turn increases its probability to pick up false positives in future
pharmacophore model based screening studies.
Trial 2: In Trial 2, compound A among training set com-
pounds A, B and C was taken as the reference compound by
giving ‘‘Principal” value of 2 and ‘‘MaxOmitFeat” value of
0. The rest of the two compounds (B and C) were given the
value of 1 for both ‘‘Principal” value and ‘‘MaxOmitFeat”
shown in Table 2. These ten different hypotheses were gener-
ated showing three different types of chemical features in
Table 3. Further, hypotheses 1, 2 and 6 showing direct hit of
1 for this training set compounds were considered for further
analysis. The corresponding variation in the scores ranges
from 62 to 55.56. The chemical features that appeared included
different combinations of ring aromatic (R), positive ionizable
(P), hydrophobic aromatic (Y), hydrophobic aliphatic (Z),
hydrogen bond donor (D) and hydrogen bond acceptor (H),
and are presented in Table 3. The best fit and fast values were
higher in this case as shown in Table 4 having good correlation
w.r.t its T-type channel activity for both hypotheses 2 and 6.
Trial 3: Akin to Trial 1 and Trial 2, two different kinds of
pharmacophore hypothesis were developed for Trial 3 in Case
I. However, in this case we observed that five and six types ofctive and non-selective hypothesis.
Distance tolerance (A˚)
Selective Hypothesis 6 Non-selective Hypothesis
6.05–8.05 6.96–8.96
4.79–6.79 3.56–5.56
9.53–11.53 5.15–7.15
3.72–5.72 3.03–5.03
13.53–15.53
5.04–7.04 7.69–9.69
5.19–7.19 4.79–6.79
5.91–7.91 4.96–6.96
9.56–11.56
tive ionizable and hydrophobic aliphatic features, to the rest of the
obic aromatic 1 and 2, Z (1) and (2): Hydrophobic aliphatic 1 and 2,
942 T. Gandhi et al.chemical features appeared from the generated ten different
hypotheses. These include, ring aromatic (R), positive ioniz-
able (P), hydrophobic aromatic (Y), hydrophobic aliphatic
(Z), hydrogen bond donor (D) and hydrogen bond acceptor
(H). In the present case we observed that the D feature was
changed to Y feature. The score ranged from 55.18 to 53.32
in the 10 hypotheses generated. However unlike the Trial 2
case, the pharmacophoric fit value was not found to be in
accordance with T-type channel activity shown in Suppl.
Table 2.
Case II: Non-selective 3D pharmacophore features
A non-selective 3D chemical feature hypothesis for the T-type
CCBs was developed in this study by including Mibefradil
(Compound D) and compound E. Both these compounds are
less selective to T-Type channel. Among three trials, Trial 1
developed by using ‘‘Principal” value of 2 and
‘‘MaxOmitFeat” value of 0 were significant in comparison
with other two trials (Table 2).
The five different types of hypothesis were obtained in this
setting. The features that appeared included different combina-
tions of ring aromatic (R), positive ionizable (P), hydrophobic
aromatic (Y), hydrophobic aliphatic (Z), hydrogen bond
donor (D) and hydrogen bond acceptor (H). Score for 10
hypotheses ranging from 53.09 to 52.13 is presented in Table 5,
respectively.
3D pharmacophore features validation
The 3D pharmacophore validation for selective and non-
selective T-type CCBs was established using chemical features,
fit values, chemical feature distances and test set molecules.
This validation includes two different case studies (Case I
and Case II) containing two different training sets, as
explained above. In each case, three different trials were per-
formed in order to check the robustness and the significance
of the developed 3D model. Ten different pharmacophoric
hypotheses were generated in each of these trials to check
the reliability of different 3D pharmacophoric features.
Case I: In this case, three different trials (Trial 1, Trial 2
and Trial 3) were made to generate three different pharma-
cophoric features containing models. These models were used
to test the importance and significance of different 3D chemi-
cal features for selective and non-selective T-Type CCBs. Trial
1 showed very weak hypothesis with less chemical features, less
score and fitness value. The percentage accuracy of pharma-
cophoric prediction using 20 test set compounds was less than
60% with both the best and fast fit methods. Thus, this trial
was discarded from the present study. Trial 2 showed some
promising results in which hypotheses 1, 2 and 6 were consid-
ered showing six to seven chemical features with good scores
and fitness value as shown in Tables 2–4. Further, hypotheses
2 and 6 of Trial 2 (Fig. 2a and b) performed well showing
direct hit of 1 for all the studied three compounds. Its accuracy
against the external test set was 85% with both fast fit and best
fit methods. The best fit and fast fit of the training set com-
pounds to these hypotheses are shown in Table 4. The corre-
sponding fitness value for the test set compounds is
promising in this trial case as shown in Table 6. Hypotheses
1, which also had a direct hit in 1 for all the studied three com-pounds was not considered, since it predicted well with fast fit
but failed in best fit method. Trial 3 even though showed five
to six chemical features with satisfactory scoring, but was
not comparable to that of hypotheses 2 and 6 of Trial 2. Fur-
ther, it completely failed in predicting the fit value w.r.t its T-
type channel activity shown in Table 4 and Suppl. Table 2.
The mapping of various chemical features of the selective
3D pharmacophore of hypotheses 2 and 6 of Case I (Trial 2)
in compounds B and C was almost similar. Hypothesis 2
contained hydrogen bond donor, positive ionizable, two
hydrophobic aliphatic, ring aromatic and hydrophobic
aromatic features. Mapping of compound A (potent and more
selective) to hypothesis 2 is shown in Fig. 3. It showed an excel-
lent fit, both by the best fit 6.97 and by the fast fit 7.00 using
hypothesis 2 (Table 4). Further, different chemical features fit-
ness toward compounds B and C include- (i) hydrogen bond
donor mapping on the terminal amine attached to alkyl chain,
(ii) positive ionizable on the nitrogen present at first position of
3, 4-dihydroquinazoline ring and (iii) hydrophobic aromatic
features mapping on the benzene ring of 3, 4-
dihydroquinazoline ring obtained using hypothesis 2. The cor-
responding best fit value of compound B was 4.59 and com-
pound C was 3.76 respectively, shown in Table 4.
Four different 3D pharmacophoric features of selective
hypothesis 6 of Case-I (Trial 2) for compounds B and C
include- (i) hydrogen bond acceptor mapping on the carbonyl
group, (ii) positive ionizable mapping on the nitrogen present
at first position of 3, 4-dihydroquinazoline ring, (iii) ring aro-
matic mapping on the phenyl ring attached to sulfonyl group,
and (iv) a hydrophobic aliphatic mapping on the ethyl substi-
tution at third position shown in Fig. 4. Two hydrophobic aro-
matic functionalities include- mapping on a phenyl of 3, 4-
dihydroquinazoline ring and the other on the phenyl ring adja-
cent to the amine group (Fig. 4). The corresponding fitness
value obtained using the best fit method for compound B
was 3.50 and compound C was 3.06 respectively (Table 4).
The compound A pharmacophore mapping was similar in
terms of hydrogen bond acceptor and one of the hydrophobic
aromatic features. They differ in terms of the positive ionizable
feature mapped on the amine substitution at second position,
w.r.t compounds B and C respectively shown in Fig. 5.
Case II: In this Case-II study, we included both selective
and non-selective T-type CCBs in the training set for 3D
HipHop pharmacophore model development. Ten different
chemical hypotheses generated using Trial 1 with ‘‘Principal”
value of 2 and ‘‘MaxOmitFeat” value of 0 produced different
combinations of five chemical features P(R)YZDH respec-
tively (Fig. 6). These hypotheses were checked for test set
(selective vs non-selective) predictions containing 20 molecules.
Among these, hypothesis 4 performed well with the external
test set accuracy of 92% (Fig. 6 and Table 6). Corresponding
best fit and fast fit value of the training set in Case-II was given
in Table 4. The mapping of compound A to hypothesis 4 is
shown in Fig. 7. The present 3D pharmacophore map contain-
ing five chemical features was in good agreement with the 3D
pharmacophore analysis performed by Doddareddy et al. [14].
Two outliers obtained in the test set compounds which were
not mapped properly were compounds 7 and 8 shown in
Table 6. On examining the chemical structure of these com-
pounds it was observed that an aliphatic –CH2CH3 at R2 posi-
tion along with the NO2 group at R3 position is present in
these compounds (Table 1). The position of R2 in other com-
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group. The nature of the substitutions at R2 and R3 in
compounds 7 and 8 might be one of the main reasons for
not mapping with the present developed pharmacophore map.
T-type CCBs selective verses non-selective pharmacophore
hypothesis
The objective of this study was to differentiate between 3D
pharmacophoric features required for selective and
non-selective T-type CCBs. Comparison of selective and
non-selective pharmacophore map showed a difference of only
one pharmacophoric feature when compared with that of the
selective hypothesis 6. The selective pharmacophore map has
six chemical features, namely ring aromatic (R), positive ioniz-
able (P), two hydrophobic aromatic (Y), hydrophobic aliphatic
(Z), hydrogen bond donor (D) and hydrogen bond acceptor
(H). On the other hand, non-selective pharmacophore map
have five chemical features lacking ring aromatic feature.
Interestingly, a comparison of hypothesis 4 in Case-II with
that of the hypothesis 2 in Case-I revealed differences of
mainly ring aromatic chemical feature in the present study,
to distinguish between selective vs. non-selective T-type CCBs.
Thus, ring aromatic feature plays an important role in deter-
mining the selectivity of T-type CCBs. Further, hydrogen bond
donor features present in the map 2 might also be important to
classify the selectivity vs. non-selectivity toward predicting T-
Type CCBs (Tables 3 and 5).
Further insight into this classification emerged by analyzing
the spatial relationship between these pharmacophoric fea-
tures. The comparative distance tolerance range of the three
hypotheses (two selectives and one non-selective) is presented
in Table 7, and is also pictorially represented in Suppl. Figs. 1,
2 and 3, respectively. The distance tolerance in three hypothe-
ses is measured from positive ionizable and hydrophilic alipha-
tic (common in three hypotheses) features of the rest of the 3D
pharmacophoric features. The distance tolerance for chemical
features P-H, P-Z1, Z1-Y1, and Z2-Y2 is nearly the same in
three hypotheses. These results suggest that the spatial relation
of this pharmacophoric features might not have any influence
on selectivity. In contrast P-Y (2) and Z-H features in selective
hypothesis (6) and non-selective hypothesis had a quite differ-
ent distance tolerance. This provides important clues that the
proper 3D spatial arrangement of these pharmacophoric fea-
tures might improve selectivity (Table 7).
Distance between positive ionizable and ring aromatic fea-
tures (P-R) in both selective hypotheses is quite different. This
indicates that the relative positioning of these two chemical
features doesn’t have any influence on the CCBs selectivity.
On the other hand, the case with Z (1) -R shows that flexibility
in the relative positioning of these two chemical features is
quite restrictive (Table 7). Selective hypothesis 2 has hydrogen
bond donor (D) and aliphatic hydrophobic feature 2 (Z2),
which are absent in hypothesis 6 and non-selective hypothesis.
The distance between P-Z2, P-HD and Z1-Z2 is given in
Table 7. This might be the other main reason contributing
for T-type CCBs selectivity using hypothesis 2. Thus, the pre-
sent study successfully highlighted the importance of the 3D
pharmacophoric features, its fit values and spatial distribu-
tions. Further, significant integration with the experimentallydetermined inhibitory activity and selectivity of different T-
Type CCBs was observed.
Conclusions
Predictive 3D pharmacophore models generated using a
HipHop module in Catalyst using selective T-type CCBs
showed six chemical features and that of the non-selective T-
type CCBs showed five chemical features. The absence of
hydrophobic feature (R) might be important for distinguishing
selective vs non-selective T-type CCBs. Further, the developed
models have the capacity to classify selective vs. non-selective
T-type CCBs on the basis of hypotheses 2 and 6 and its corre-
sponding pharmacophoric fit value and distance analysis.
These 3D models provide a useful framework for understand-
ing binding and gave structural insight into the specific CCBs–
receptor interactions responsible for affinity, and other biolog-
ical processes.
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